AbbVie Licenses Phase II-Ready Antibody Programme to Receptos for Development in Eosinophilic Oesophagitis
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 4 (Table of Contents)
Published: 2 Apr-2013
DOI: 10.3833/pdr.v2013.i4.1914 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Abbott spin-off AbbVie has licensed a deprioritised antibody programme to Receptos as part of a risk-sharing deal that allows the big pharma company to opt back into development and commercialisation of the drug candidate should it demonstrate proof-of-concept in the treatment of the orphan disease eosinophilic oesophagitis...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS